• Jeffrey Loh and Amitabh Gulati.
• Department of Anesthesiology, University of California Los Angeles, Los Angeles, California, USA.
• Pain Med. 2015 Jun 1; 16 (6): 120412101204-10.

BackgroundCancer pain is difficult to treat, often requiring a multimodal approach. While medication management remains the mainstay for the treatment of cancer pain, medications are often associated with undesired side effects. Transcutaneous electrical nerve stimulation (TENS) provides a potential adjunctive method for treating cancer pain with minimal side effects.ObjectiveFew studies have been performed evaluating the efficacy of TENS on cancer pain. We sought to examine the usefulness of TENS on all cancer patients and to specifically look at the use of TENS as a goal-directed therapy to improve functionality.DesignRetrospective cohort study.MethodsSince 2008, patients with chronic cancer pain and on multimodal pain regimens were trialed with TENS. Those patients who showed an improvement in pain symptoms or severity were educated about and provided with a TENS unit for use at home. Pain symptoms and scores were monitored with the visual analog scale (VAS), the numerical rating pain (NRP) scale, and Short-Form McGill Questionnaire at the start of TENS treatment and at 2 months follow-up.ResultsTENS proved beneficial in 69.7% of patients over the course of 2 months. In TENS responsive patients, VAS scores decreased by 9.8 on a 0-100 mm scale (P < 0.001), and NRP scores decreased by 0.8 on a 1-10 scale (P < 0.001).LimitationsLack of placebo and lack of blinding of physician and patient.ConclusionsTENS provides a beneficial adjunct for the treatment of cancer pain, especially when utilized as a goal-directed therapy.Wiley Periodicals, Inc.

33 keywords...

hide…